0
Pulmonary Vascular Disease: PAH |

Effects of Riociguat in Treatment-Naive vs Pretreated Patients With Pulmonary Arterial Hypertension: 2-Year Efficacy Results From the PATENT-2 Study

J. Wesley McConnell, MD; Peter Engel, MD; Franz Rischard, DO; Stephan Rosenkranz, MD; Carmine Dario Vizza, MD; Arno fritsch, PhD; Janethe de Oliveira Pena, MD; Hossein Ardeschir Ghofrani, MD
Author and Funding Information

Division of Pulmonary and Critical Care Medicine, University of Kentucky Medical Center, Kentucky, KY


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):1162A. doi:10.1016/j.chest.2016.08.1271
Text Size: A A A
Published online

Extract

SESSION TITLE: PAH

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, October 23, 2016 at 01:30 PM - 03:00 PM

PURPOSE: Riociguat showed sustained efficacy in patients with PAH in the PATENT-2 study. We compared treatment-naïve and pretreated patients from the final data cut of PATENT-2.

METHODS: Patients with PAH who were treatment-naïve or pretreated with endothelin receptor antagonists (ERAs) or prostanoids entered PATENT-2 after completing PATENT-1 without ongoing riociguat-related SAEs. All patients received riociguat individually adjusted up to a maximum of 2.5 mg tid. Primary endpoints were safety and tolerability; secondary endpoints included 6-minute walking distance (6MWD), WHO functional class (FC), survival, and clinical worsening-free survival.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543